The claim that these drugs quiet the urge to drink started as an anecdote, became a pharmacovigilance signal, and has now been tested twice in randomized trials. That progression is unusual and worth following closely, because it is the rare case where the internet got to an answer before the literature did and the literature then broadly agreed. What none of it changes is what these drugs are sold for: every seller on this site’s roundup prescribes them for weight, and none of them prescribes for this.
The larger trial
A 26-week single-center trial randomized 108 treatment-seeking adults with moderate to severe alcohol use disorder and co-existing obesity to weekly semaglutide at 2.4 mg or placebo, with standard cognitive behavioral therapy in both arms [1]. Heavy drinking days fell 41.1 percentage points from baseline on semaglutide and 26.4 points on placebo, an estimated treatment difference of 13.7 points (95% CI −22.0 to −5.4, p=0.0015). Eighty-one percent of participants completed the full intervention.
The placebo arm is the part worth sitting with. It fell by more than a quarter on therapy alone. Semaglutide added to that rather than replacing it, and the trial cannot say what the drug would do without the therapy because it never tested that.
The smaller, earlier trial
A phase 2 trial published a year earlier randomized 48 adults with alcohol use disorder who were not seeking treatment, gave nine weeks of low-dose semaglutide topping out at 1.0 mg, and measured drinking in a laboratory task [2]. It found medium to large effects on grams of alcohol consumed (β −0.48, 95% CI −0.85 to −0.11) and on peak breath alcohol concentration (β −0.46, 95% CI −0.87 to −0.06), plus lower drinks per drinking day and lower weekly craving.
It also found nothing on two outcomes: average drinks per calendar day and the number of drinking days did not move. People drank on the same days and drank less when they did. That is a specific finding, not a weaker version of the big trial’s.
What the large observational data adds
A retrospective cohort of electronic health records covering 83,825 patients with obesity found semaglutide associated with a 50% to 56% lower rate of both incidence and recurrence of alcohol use disorder over 12 months, compared with other anti-obesity medications[4]. The direction was consistent across sex, age group, race, and diabetes status, and replicated in 598,803 patients with type 2 diabetes.
Cohorts of that size are good at showing that a small effect is real and bad at showing how big it is, because people who are prescribed one drug differ from people prescribed another in ways no adjustment fully removes. The trials are the evidence for the size; the cohort is the evidence that it generalizes past a single clinic.
The part that matters for anyone buying online
None of this is an approved use. The trials used brand semaglutide at fixed doses under supervision, with therapy attached in the larger one. A reader who buys a compounded vial from a telehealth storefront hoping for this effect is buying a different thing: a preparation the FDA does not review before dispensing, at a dose the seller often will not state, from a service whose escalation schedule is usually unpublished. We count how rarely that last part is written down in who publishes a dose ladder, and list every seller that does in the published ladders tool.
It also matters that both trials ran at doses on the escalation path rather than at the starting rung. What a price does between those two points is the single most common silence in this market, counted in what sellers will not tell you. And if the reason for interest is the drug’s effect on appetite and reward more broadly, the trial evidence for the weight outcome itself is worth reading first in what the semaglutide trials are worth.